The drug Avastin, when added to initial therapy for glioblastoma, can give patients a few extra months’ reprieve before their brain tumors start growing again, but does it make their quality of life better – or worse?
That’s a matter of heated debate for doctors – and confusion for patients – after two large clinical trials reported conflicting results at the annual American Society of Clinical Oncology (ASCO) conference in June. Some experts contend that Avastin lacked sufficient benefit for use as an “upfront” treatment for glioblastomas – the most common and aggressive brain tumors.